Implanet announces publication of a cost effectiveness study of JAZZ™ Band in Adolescent Idiopathic Scoliosis

- Study conducted by Health Advances, a highly respected healthcare strategy firm
- JAZZ contributes ~$11,700 of incremental profit per AIS procedure

Bordeaux, Boston, March 24, 2015 — IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specialized in vertebral and knee-surgery implants, today announces publication of a retrospective cost effectiveness study documenting the potential economic benefit of the JAZZ™ Band in scoliosis surgery.

Ludovic Lastennet, CEO of Implant, says: “The clinical results of sublaminar band technology used in a hybrid construct in the treatment of Adolescent Idiopathic Scoliosis (AIS), are well documented. This study is the first of its kind, documenting the incremental profit potential of JAZZ when used in AIS treatment. The dramatic benefits highlighted in this research illustrate Implant’s continued commitment to delivering technological advancements for improved patient outcomes, enhancing procedural safety for the clinical team, and making a positive economic impact on the hospital’s bottom line.”

Health Advances analyzed key hospital cost metrics for two implant configurations in the surgical treatment of AIS: all pedicle screw constructs and hybrid constructs consisting of pedicle screws and sublaminar bands. The following benefits were demonstrated with JAZZ Band hybrid constructs:

- Reduced number of implants per case
- Decreased procedure length
- Reduced blood loss
- Reduced duration of hospital stay

Savings in these metrics, along with incremental revenue opportunities, result in approximately $11,700 of incremental profit per AIS procedure using a JAZZ hybrid construct. In addition, the research quantified a substantial reduction in radiation exposure to the patient, surgeon and operating room staff when utilizing a JAZZ hybrid construct.

Doria Cole, Health Advances Consultant and co-author, states: “This thorough study included a comprehensive review of the published literature in conjunction with an analysis of retrospective data from 32 AIS cases using Jazz and qualitative spine surgeon feedback. The results are particularly relevant in today’s healthcare environment, with increased focus on optimizing clinical outcomes in the most efficient and economical manner possible.”

The paper, entitled ‘Retrospective Cost Effectiveness Analysis of Implant Jazz Sublaminar Bands for Surgical Treatment of Adolescent Idiopathic Scoliosis’ is co-authored by Brice Ilharreborde, MD, PhD, APHP - Hospital Robert Debré in Paris, Raymund Woo, MD, Florida Center for Pediatric Orthopaedics, and Doria Cole, Health Advances, and is available at www.implanet.com.

Implanet will attend the AAOS congress

Implanet is attending the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, the world’s largest conference dedicated to orthopedics, which this year will bring together more than 15,000 orthopedic surgeons from around the world. Implant will be at Booth 130 from March 25 to 27 to present its JAZZ technological platform devoted to spine surgery and promote the results of the Health Advance medico-economic study. Among other topics, this 2015 edition of the AAOS Annual Meeting will focus on research and the latest clinical breakthroughs in the field of spine surgery.
About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2014 sales of €7.0 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.

IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.
Ticker: IMPL - ISIN code: FR0010458729

IMPLANET
Ludovic Lastennet
CEO
Tel.: +33 (0)5 57 99 55 55
investors@implanet.com

NewCap
Investor Relations
Florent Alba
Tel.: +33 (0)1 44 71 94 94
implanet@newcap.fr

NewCap
Press Relations
Nicolas Mérigeau
Tel.: +33 (0)1 44 71 94 98
implanet@newcap.fr